| 國家衛生研究院 |
2023-08-31 |
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
|
Vistisen, D; Carstensen, B; Elisabetta, P; Lanzinger, S; Tan, ECH; Yabe, D; Kim, DJ; Sheu, WHH; Melzer-Cohen, C; Holl, RW; Núñez, J; Ha, KH; Halvorsen, S; Langslet, G; Karasik, A; Nyström, T; Niskanen, L; Guleria, S; Klement, R; Carrasco, M; Foersch, J; Shay, C; Koeneman, L; Hoti, F; Farsani, SF; Khunti, K; Zaccardi, F; Subramanian, A; Nirantharakumar, K; EMPRISE EU and East Asia Study Group |
